Catalyst Pharmaceuticals, Inc.
US ˙ NASDAQCM ˙ US14888U1016 ˙ Medical Devices
DIESES SYMBOL IST NICHT MEHR AKTIV

SecurityCPRX / Catalyst Pharmaceuticals, Inc.
InstitutionFSSNX - Fidelity Small Cap Index Fund
Latest Disclosed Ownership1,143,620 shares
Latest Disclosed Value $ 32,170,030
FSSNX - Fidelity Small Cap Index Fund reports 2.25% increase in ownership of CPRX / Catalyst Pharmaceuticals, Inc.

On June 26, 2026 - FSSNX - Fidelity Small Cap Index Fund filed a NPORT-P form disclosing ownership of 1,143,620 shares of Catalyst Pharmaceuticals, Inc. (US:CPRX) valued at $32,170,031 USD as of April 30, 2026. The entity filed a previous NPORT-P on March 25, 2026 disclosing 1,118,413 shares of Catalyst Pharmaceuticals, Inc.. This represents a change in shares of 2.25% during the quarter. The current value of the position is $36,012,594 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date		 Effective
Date		Form Security Class ID Avg Price
Paid (Est)		 Reported
Shares		 ΔShares ΔShares
(%)		 Reported
Value
(x1000)		 ΔValue
(%)		 Alloc
(%)		 ΔAlloc ΔAlloc (%) Cost Basis
(x1000)		 Unrealized
Gain/Loss
(x1000)
2026-06-26 2026-04-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 1,143,620 25,207 2.25 32,170 18.37 0.0988
2026-03-25 2026-01-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 1,118,413 -45,132 -3.88 27,177 9.81 0.0914
2025-12-23 2025-10-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 1,163,545 450 0.04 24,749 -0.24 0.0852
2025-09-26 2025-07-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 1,163,095 20,652 1.81 24,809 -10.60 0.0958
2025-06-26 2025-04-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 1,142,443 39,569 3.59 27,750 11.53 0.1172
2025-03-31 2025-01-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 1,102,874 -39,833 -3.49 24,881 -0.12 0.0916
2024-12-26 2024-10-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 1,142,707 -78,694 -6.44 24,911 18.31 0.0927
2024-09-25 2024-07-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 1,221,401 114,802 10.37 21,057 26.43 0.0738
2024-06-28 2024-04-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 1,106,599 89,968 8.85 16,654 13.76 0.0674
2024-03-27 2024-01-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 1,016,631 46,855 4.83 14,639 21.65 0.0590
2023-12-29 2023-10-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 969,776 107,528 12.47 12,035 0.92 0.0595
2023-09-25 2023-07-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 862,248 24,978 2.98 11,925 -10.54 0.0525
2023-06-27 2023-04-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 837,270 37,179 4.65 13,329 7.55 0.0676
2023-03-27 2023-01-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 800,091 45,330 6.01 12,393 18.39 0.0595
2022-12-28 2022-10-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 754,761 11,467 1.54 10,469 37.54 0.0549
2022-09-27 2022-07-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 743,294 0 0.00 7,611 34.40 0.0400
2022-06-24 2022-04-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 743,294 21,012 2.91 5,664 36.13 0.0303
2022-03-22 2022-01-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 722,282 -12,483 -1.70 4,160 -4.04 0.0212
2021-12-21 2021-10-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 734,765 -6,293 -0.85 4,335 0.18 0.0191
2021-09-24 2021-07-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 741,058 -5,420 -0.73 4,328 26.59 0.0202
2021-06-28 2021-04-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 746,478 77,288 11.55 3,419 40.37 0.0161
2021-03-17 2021-01-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 669,190 -96,583 -12.61 2,436 7.08 0.0138
2020-12-18 2020-10-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 765,773 145,860 23.53 2,274 -14.67 0.0185
2020-09-18 2020-07-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 619,913 38,050 6.54 2,666 -3.37 0.0234
2020-06-17 2020-04-30 NP CATALYST PHARMACEUTICALS EC US14888U1016 581,863 76,352 15.10 2,758 32.79 0.0279
2020-03-27 2020-01-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 505,511 28,910 6.07 2,078 -7.85 0.0194
2019-12-23 2019-10-31 NP CATALYST PHARMACEUTICALS EC US14888U1016 476,601 476,601 2,254 0.0229
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.